CytomX Therapeutics Management

Management criteria checks 3/4

CytomX Therapeutics' CEO is Sean McCarthy, appointed in Aug 2011, has a tenure of 12.75 years. total yearly compensation is $2.61M, comprised of 25% salary and 75% bonuses, including company stock and options. directly owns 0.78% of the company’s shares, worth €809.59K. The average tenure of the management team and the board of directors is 3.1 years and 4.3 years respectively.

Key information

Sean McCarthy

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage	25.0%
CEO tenure	12.8yrs
CEO ownership	0.8%
Management average tenure	3.1yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sean McCarthy's remuneration changed compared to CytomX Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$3m	US$652k	-US$569k
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$42m
Mar 31 2023	n/a	n/a	-US$71m
Dec 31 2022	US$3m	US$623k	-US$99m
Sep 30 2022	n/a	n/a	-US$149m
Jun 30 2022	n/a	n/a	-US$143m
Mar 31 2022	n/a	n/a	-US$132m
Dec 31 2021	US$4m	US$616k	-US$116m
Sep 30 2021	n/a	n/a	-US$72m
Jun 30 2021	n/a	n/a	-US$64m
Mar 31 2021	n/a	n/a	-US$61m
Dec 31 2020	US$3m	US$595k	-US$65m
Sep 30 2020	n/a	n/a	-US$54m
Jun 30 2020	n/a	n/a	-US$63m
Mar 31 2020	n/a	n/a	-US$76m
Dec 31 2019	US$4m	US$575k	-US$133m
Sep 30 2019	n/a	n/a	-US$99m
Jun 30 2019	n/a	n/a	-US$99m
Mar 31 2019	n/a	n/a	-US$83m
Dec 31 2018	US$5m	US$550k	-US$85m
Sep 30 2018	n/a	n/a	-US$52m
Jun 30 2018	n/a	n/a	-US$39m
Mar 31 2018	n/a	n/a	-US$50m
Dec 31 2017	US$3m	US$500k	-US$43m

Compensation vs Market: Sean's total compensation ($USD2.61M) is above average for companies of similar size in the German market ($USD400.67K).

Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.

CEO

Sean McCarthy (56 yo)

12.8yrs

Tenure

US$2,611,138

Compensation

Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sean McCarthy	Chairman & CEO	12.8yrs	US$2.61m	0.78% $ 809.6k
Marcia Belvin	Senior VP & Chief Scientific Officer	1.3yrs	US$1.21m	0.088% $ 90.8k
Jeffrey Landau	Senior VP	3.1yrs	US$1.05m	0.078% $ 80.9k
Christopher Ogden	Senior VP of Finance & Accounting	2.8yrs	no data	0.037% $ 38.8k
Lloyd Rowland	Senior VP	6yrs	US$1.21m	0.096% $ 99.0k
Danielle Olander-Moghadassian	Senior VP & Chief Human Resources Officer	no data	no data	no data
Leslie Robbins	Senior Vice President of Intellectual Property	5.3yrs	no data	no data
Yu-Waye Chu	Chief Medical Officer	less than a year	no data	no data
Dawn Benson	Senior Vice President of Quality & Product Manufacturing	1.3yrs	no data	no data
Hoyoung Huh	Special Advisor to Chief Executive Officer	no data	US$273.54k	no data

3.1yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 6C1's management team is considered experienced (3.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sean McCarthy	Chairman & CEO	12.8yrs	US$2.61m	0.78% $ 809.6k
Elaine Jones	Independent Director	5yrs	US$75.12k	0.0076% $ 7.9k
John Lambert	Member of Scientific Advisory Board	4.3yrs	no data	no data
Louis Weiner	Member of Scientific Advisory Board	no data	no data	no data
Mani Mohindru	Independent Director	3.4yrs	US$76.98k	0% $ 0
James Meyers	Independent Director	5.4yrs	US$77.69k	0% $ 0
Matthew Young	Lead Independent Director	8.7yrs	US$106.49k	0% $ 0
Halley Gilbert	Independent Director	4.1yrs	US$80.62k	0% $ 0
W. Kavanaugh	Member of Scientific Advisory Board	3.4yrs	US$8.03m	no data
Alan Ashworth	Independent Director	2.7yrs	US$68.89k	0% $ 0
Charles Sentman	Member of Scientific Advisory Board	4.3yrs	no data	no data
Lisa Coussens	Member of Scientific Advisory Board	1.3yrs	no data	no data

4.3yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 6C1's board of directors are considered experienced (4.3 years average tenure).

CytomX Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

CytomX Therapeutics, Inc., Annual General Meeting, May 15, 2024

CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors

CytomX Therapeutics, Inc. Appoints Yu-Waye Chu as Chief Medical Officer

High number of new and inexperienced directors

CytomX Therapeutics, Inc. Announces Executive Changes

Cytomx Therapeutics, Inc. to Terminate Carlos Campoy as Chief Financial Officer, Effective as of September 30, 2022

Recent updates

CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors

CytomX Therapeutics, Inc., Annual General Meeting, May 15, 2024

CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors

Full year 2023 earnings released: US$0.008 loss per share (vs US$1.51 loss in FY 2022)

CytomX Therapeutics, Inc. to Report Q4, 2023 Results on Mar 11, 2024

New minor risk - Market cap size

CytomX Therapeutics, Inc. Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

New minor risk - Profitability

Forecast breakeven date pushed back to 2024

Third quarter 2023 earnings released: EPS: US$0.037 (vs US$0.35 loss in 3Q 2022)

Forecast to breakeven in 2023

CytomX Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CytomX Therapeutics, Inc. Presents Preclinical Profile of EpCAM-Directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

CytomX Therapeutics, Inc. announced that it has received $30 million in funding

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.37 loss in 2Q 2022)

CytomX Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

CytomX Therapeutics, Inc. Appoints Yu-Waye Chu as Chief Medical Officer

New minor risk - Market cap size

First quarter 2023 earnings released: US$0.05 loss per share (vs US$0.36 loss in 1Q 2022)

Full year 2022 earnings released: US$1.51 loss per share (vs US$1.81 loss in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.35 loss per share (vs US$0.35 loss in 3Q 2021)

CytomX Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CytomX Therapeutics, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.30 loss in 2Q 2021)

CytomX Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Cytomx Therapeutics, Inc. to Terminate Carlos Campoy as Chief Financial Officer, Effective as of September 30, 2022

CytomX Therapeutics, Inc. Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.26 loss in 1Q 2021)

High number of new directors

Cytomx Therapeutics Announces Retirement of John A. Scarlett from Board of Directors and Chair of the Compensation Committee and A Member of the Audit Committee

CytomX Therapeutics, Inc., Annual General Meeting, Jun 15, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

CytomX Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Cytomx Therapeutics, Inc. Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer

CytomX Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors

CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029

Third quarter 2021 earnings released: US$0.35 loss per share (vs US$0.32 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.30 loss per share (vs US$0.34 loss in 2Q 2020)

CytomX Therapeutics, Inc. Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.27 profit in 1Q 2020)

Full year 2020 earnings released: US$0.71 loss per share (vs US$2.26 loss in FY 2019)

Revenue beats expectations

CytomX Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: €7.42

New 90-day high: €6.65

CytomX Therapeutics, Inc. Appoints Dr. Mani Mohindru to Board of Directors

New 90-day high: €6.60

Revenue beats expectations

Third quarter 2020 earnings released: US$0.32 loss per share

CytomX Therapeutics, Inc. Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate

CytomX Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020

CytomX Therapeutics, Inc. Announces Planned Retirement of W. Michael Kavanaugh, Chief Scientific Officer, Head of Research and Non-Clinical Development on December 1, 2020

New 90-day low - €5.55

First half earnings released

New 90-day low - €6.40

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age